



Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

May 15, 2024

SAN DIEGO--(BUSINESS WIRE)--May 15, 2024-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific conferences:

TIDES USA: Oligonucleotide and Peptide Therapeutics (Presentation)

- Thursday, May 16, 2024 (4:45 p.m. ET)

H.C. Wainwright 2nd Annual BioConnect Investor Conference as NASDAQ (Fireside Chat)

- Monday, May 20, 2024 (2:30 p.m. ET)

Piper Sandler Lung Investor Conference (Fireside Chat)

- Thursday, May 23, 2024 (2:30 p.m. ET)

Goldman Sachs 45th Annual Healthcare Conference (Fireside Chat)

- Wednesday, June 12, 2024 (2:40 p.m. ET)

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240515675057/en/): <https://www.businesswire.com/news/home/20240515675057/en/>

IR and Media Contacts

Arcturus Therapeutics
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com

Source: Arcturus Therapeutics Holdings Inc.